- Global Pharma News & Resources

Rising mycosis fungoides incidence rate will boost the folliculotropic mycosis fungoides treatment market, forecast to grow at a CAGR of 15%

Noida, Uttar Pradesh, India, February 25 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global Folliculotropic Mycosis Fungoides Treatment Market is estimated to see healthy growth, pegged at a CAGR of ~15% during the forecast period 2020-2025. The rising incidence rate of mycosis fungoides among adults is one of the significant factors expects to boost the folliculotropic mycosis fungoides treatment market growth worldwide. Rising investment in research areas to develop an effective treatment solution with ongoing clinical studies expected to propel the market growth. Collaboration between the hospitals and research labs can benefit the scope of treatment with new findings like novel immunotherapy drugs.

To Get the Sample Copy of Report Visit @

Increasing awareness about the disease, rising large patient population base with a weak immune system, growing lymphoma cancer cases are factors influencing the growth of folliculotropic mycosis fungoides treatment market. The growing geriatric population and the rise in wealth in developed and developing countries drive the demand for folliculotropic mycosis fungoides treatment.

However, affluent consumers, being more concerned about health, and raising awareness about early treatment contribute to the folliculotropic mycosis fungoides treatment market. The regulatory approvals for special drug designation for treatment, strong R&D pipeline expects to propel the folliculotropic mycosis fungoides treatment market growth in the coming future.

Rendering to the National Institute of Health (NIH), the overall incidence of cutaneous T-cell lymphoma was around 10.2 per million persons. The mycosis fungoides associated cases were found to be more than half of the cutaneous T-cell lymphoma cases, with an incidence of 5.6 per million persons.

The various pharmaceutical and biotechnology companies focus on research areas to capture the highly effective treatment’s unmet needs to provide an effective long-term treatment. Concurrently, investments for increasing the production of folliculotropic mycosis fungoides products are showing increasing growth.

North America is dominating the folliculotropic mycosis fungoides treatment market due to the increasing prevalence of folliculotropic mycosis fungoide among the American countries’ growing geriatric population. The presence of major key players in North America like Pfizer Inc., Astellas, and other key players is witnessing the region’s persisting strong R&D background with increased healthcare expenditure. Urbanization in the emerging economies has led to a rise in economic standards and changing consumer preference for self-care with increased capacity for rare disease treatment.

Segmentation Overview of the Global Folliculotropic Mycosis Fungoides Treatment Market

The folliculotropic mycosis fungoides treatment market has been segmented into Type, Drug Type, Therapy, and End Users. These major market segments are further categorized into various sub-segments to study the market in detail.

By Type Outlook (Small molecule, Biologics)
By Drug Type Outlook (Topical Steroids, Antineoplastic agents, Interferons, Others)
By Therapy Outlook (Radiation Therapy, Photodynamic Therapy, Targeted Therapy, Chemotherapy, Drug Therapy, Immunotherapy, Psoralen Plus Ultraviolet A, Ultraviolet B)
By End Users Outlook (Hospitals, Speciality Clinics, Others)

Key Players Insights

Takeda Pharmaceutical Company Ltd., Merck & Co. Inc., Seattle Genetics, Inc., Kyowa Kirin Co. Ltd., Eisai Co., Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc., Celegene Corporation, Azurity Pharmaceuticals Inc., Elorac, Soligenix, and Actelion pharmaceuticals Ltd., among others, are some significant players included in the research study of the global folliculotropic mycosis fungoides treatment market.

Download Detailed Sample Report at @

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 25-Feb-2021